# OnCo record ret-fusion-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ret-fusion-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ret-fusion-nsclc" ;
  schema:name "RET fusion-positive non-small-cell lung cancer"@en ;
  schema:alternateName "RET-rearranged lung cancer"@en, "KIF5B-RET lung cancer"@en, "RET+ NSCLC"@en ;
  schema:description "RET fusion lung cancer is a rare adenocarcinoma driven by a fused RET gene. The selective pill selpercatinib shrinks most tumours and more than doubles the time to progression compared with chemotherapy and immunotherapy, and pralsetinib is a second option."@en ;
  schema:url <https://onco.cc/cancers/ret-fusion-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/RET_proto-oncogene> ;
  schema:citation <https://en.wikipedia.org/wiki/RET_proto-oncogene>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/radiosurgery-srs/> ;
  onco:targets <https://onco.cc/targets/ret/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/blueprint-medicines/> ;
  onco:pathways <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/tki-term/> ;
  onco:trials <https://onco.cc/trials/libretto-431/>, <https://onco.cc/trials/nct03157128/> ;
  onco:people <https://onco.cc/people/alexander-drilon/>, <https://onco.cc/people/justin-gainor/>, <https://onco.cc/people/zhou-caicun/> ;
  onco:pipeline <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/trials/libretto-431/> ;
  onco:standardOfCare <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/trials/libretto-431/>, <https://onco.cc/trials/nct03157128/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/terms/gatekeeper-mutation/> .